Connaught Laboratories Limited

Aventis Pasteur Limited

Engineered Antigens Inc.

Other

University of Saskatchewan

University Technologies International, Inc.

Transgene S.a.

Pasteur Merieux Serums Et Vaccins

The Board of Governors of the University

Anthony Bernard Schryvers

Michel Henri Klein

Sheena M Loosmore

Yan-Ping Yang

Robin E Harkness

Pele Chong

Andrew D Murdin

Scott Gray-Owen

Run-Pan Du

Scott D Gray-Owen

Lisa E Myers

Robert A Bonnah

Trevor F Moraes

Andrew A Potter

Christine Chieh-Lin Lai

Andrew Judd

Yogesh Hooda

Eric Jacobs

Clement R Rioux

Marie-Aline Bloch

Bernadette Bouchon-Theisen

Reggie Y C Lo

V&eacute;ronique Mazarin

Mich&egrave;le LeGrain

Michele Legrain

Veronique Mazarin

Novel methods for exporting target proteins from the cytosol to the extracellular surface of bacterial cells are provided. The methods are useful in that they permit the preparation of vaccines for the prevention of bacterial infectious diseases.

SLAM polynucleotides and polypeptides and uses thereof

The present disclosure relates to methods for exporting target proteins (e.g., surface lipoproteins) from the cytosol to the extracellular surface of bacterial cells using surface lipoprotein assembly modulator (SLAM) polypeptides. The use of SLAM polypeptides in a method of preparing vaccines useful in the prevention of bacterial infectious diseases is also taught.

The disclosure provides immunogenic compositions comprising a polypeptide comprising a C-lobe domain or an N-lobe domain of a HIBP surface receptor protein obtainable from or obtained from a Gram-negative bacterial species. The HIBP surface receptor proteins have been modified in such a manner that they are unable to bind host iron binding protein. Methods of making and using these immunogenic positions to prepare animal and human vaccines are also provided.

Immunogenic compositions and vaccines derived from bacterial surface receptor proteins

Purified and isolated nucleic acid molecules are provided which encode Tbp2 proteins ofstrains M35, 3 and LES1. The nucleic acid sequence may be used to produce recombinant Tbp2 proteins of the strain offree of other proteins of thestrain for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecules may be used in the diagnosis of infection.

[object Object]

Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain ofor a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbp1 or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.

Transferrin receptor genes

Cloning and expression of genes encodingtransferrin-binding proteins are described. The transferrin-binding proteins can be used in vaccine compositions for the prevention and treatment ofinfections, as well as in diagnostic methods for determining the presence ofinfections.

Cloning and expression of Haemophilus somnus transferrin-binding proteins

Novel transferrin binding proteins from , and nucleic acid molecules encoding the novel proteins are disclosed. Antibodies against the novel proteins are disclosed. The invention also relates to vaccines containing the novel proteins of the invention. The invention also provides methods for identifying substances which affect the binding of transferrin to the proteins and methods for screening for agonists or antagonists of the binding of the proteins and transferrin.

Transferrin binding proteins of Pasteurella haemolytica and vaccines containing same

Purified and isolated nucleic acid molecules are provided which encode transferrin receptor proteins of Moraxella, such as or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce recombinant transferrin receptor proteins Tbp1 and Tbp2 of the strain of Moraxella free of other proteins of the Moraxella strain for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection.

Transferrin receptor genes of Moraxella

Transferrin receptor of moraxella

Cloning and expression of genes encoding transferrin-binding proteins are described. The transferrin-binding proteins can be used in vaccine compositions for the prevention and treatment of infections, as well as in diagnostic methods for determining the presence of infections.

Vaccine compositions comprising Haemophilus somnus transferrin-binding proteins and methods of use

Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbp1 or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.

Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbpl or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.

Haemophilus transferrin receptor genes

An isolated and purified lactoferrin receptor protein is isolated and purified from bacterial pathogens, including Moraxella and Neisseria, and has a molecular weight of between about 70,000 and about 90,000, as determined by SDS-PAGE. Such lactoferrin receptor protein may be provided in combination with a lactoferrin receptor protein from the bacterial pathogen of a molecular weight of about 100,000 to about 105,000 daltons. The lactoferrin receptor protein may be produced by providing a solubilized membrane preparation from the bacterial pathogen containing lactoferrin receptor proteins, non-lactoferrin receptor proteins and other contaminants, complexing the lactoferrin receptor proteins with lactoferrin and purifying the resulting complexes substantially free from the non-lactoferrin receptor proteins and the other contaminants, and separating the novel lactoferrin receptor protein from the complexes. The lactoferrin receptor protein is useful in diagnostic applications and immunogenic compositions, particularly for in vivo administration to a host to confer protection against disease caused by a bacterial pathogen that produces the lactoferrin receptor protein or produces a protein capable of inducing antibodies in a host specifically reactive with the lactoferrin receptor protein.

Growing community of inventors

Calgary, Canada

Anthony Bernard Schryvers